Health Impact and Cost-Effectiveness of HIV Testing, Linkage, and Early Antiretroviral Treatment in the Botswana Combination Prevention Project
Open Access
- 14 April 2022
- journal article
- research article
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 90 (4) , 399-407
Abstract
Background: The Botswana Combination Prevention Project tested the impact of combination prevention (CP) on HIV incidence in a community-randomized trial. Each trial arm had ∼55,000 people, 26% HIV prevalence, and 72% baseline ART coverage. Results showed intensive testing and linkage campaigns, expanded antiretroviral treatment (ART), and voluntary male medical circumcision referrals increased coverage and decreased incidence over ∼29 months of follow-up. We projected lifetime clinical impact and cost-effectiveness of CP in this population. Setting: Rural and periurban communities in Botswana. Methods: We used the Cost-Effectiveness of Preventing AIDS Complications model to estimate lifetime health impact and cost of (1) earlier ART initiation and (2) averting an HIV infection, which we applied to incremental ART initiations and averted infections calculated from trial data. We determined the incremental cost-effectiveness ratio [US$/quality-adjusted life-years (QALY)] for CP vs. standard of care. Results: In CP, 1418 additional people with HIV initiated ART and an additional 304 infections were averted. For each additional person started on ART, life expectancy increased 0.90 QALYs and care costs increased by $869. For each infection averted, life expectancy increased 2.43 QALYs with $9200 in care costs saved. With CP, an additional $1.7 million were spent on prevention and $1.2 million on earlier treatment. These costs were mostly offset by decreased care costs from averted infections, resulting in an incremental cost-effectiveness ratio of $79 per QALY. Conclusions: Enhanced HIV testing, linkage, and early ART initiation improve life expectancy, reduce transmission, and can be cost-effective or cost-saving in settings like Botswana.Keywords
This publication has 24 references indexed in Scilit:
- Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness AnalysesJAMA, 2016
- The Anticipated Clinical and Economic Effects of 90–90–90 in South AfricaAnnals of Internal Medicine, 2016
- Botswana's progress toward achieving the 2020 UNAIDS 90-90-90 antiretroviral therapy and virological suppression goals: a population-based surveyThe Lancet HIV, 2016
- Systematic review and meta-analysis of community and facility-based HIV testing to address linkage to care gaps in sub-Saharan AfricaNature, 2015
- Performance of Rapid HIV Testing by Lay Counselors in the Field During the Behavioral and Biological Surveillance Survey Among Female Sex Workers and Men Who Have Sex With Men in BotswanaJAIDS Journal of Acquired Immune Deficiency Syndromes, 2015
- Dolutegravir plus Abacavir–Lamivudine for the Treatment of HIV-1 InfectionNew England Journal of Medicine, 2013
- Cost-Effectiveness of HIV Treatment as Prevention in Serodiscordant CouplesNew England Journal of Medicine, 2013
- Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysisAIDS, 2009
- Cost-Effectiveness of HIV Treatment in Resource-Poor Settings — The Case of Côte d'IvoireNew England Journal of Medicine, 2006
- Early chemoprophylaxis with trimethoprim-sulphamethoxazole for HIV-1-infected adults in Abidjan, Côte d'Ivoire: a randomised trialThe Lancet, 1999